Loading
A phase 3 trial of Ivonescimab in small-cell lung cancer, run by Akeso, now recruiting.
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy is a phase 3 interventional study registered as NCT07010263 by Akeso, with 560 participants planned, started 2025-06-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: AK112, Placebo. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.